Back to Journals » Drug Design, Development and Therapy » Volume 15

A Review of Drug Therapy in Vestibular Schwannoma

Authors Long J, Zhang Y, Huang X, Ren J, Zhong P, Wang B

Received 3 September 2020

Accepted for publication 11 December 2020

Published 8 January 2021 Volume 2021:15 Pages 75—85

DOI https://doi.org/10.2147/DDDT.S280069

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Manfred Ogris


Jianfei Long,1,* Yu Zhang,1,* Xiang Huang,2 Junwei Ren,2 Ping Zhong,2 Bin Wang1

1Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China; 2Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, People’s Republic of China

*These authors contributed equally to this work

Correspondence: Ping Zhong
Department of Neurosurgery, Huashan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai 200040, People’s Republic of China
Email zhp228899@163.com
Bin Wang
Department of Pharmacy, Huashan Hospital, Fudan University, No. 12 Middle Wu Lu Mu Qi Road, Shanghai 200040, People’s Republic of China
Tel +86 13916606721
Email wangbin@huashan.org.cn

Abstract: Vestibular schwannomas (VSs, also known as acoustic neuromas) are benign intracranial tumors commonly managed with observation, surgery, and radiotherapy. There is currently no approved pharmacotherapy for VS patients, which is why we conducted a detailed search of relevant literature from PubMed and Web of Science to explore recent advances and experiences in drug therapy. VSs feature a long course of disease that requires treatment to have minimal long-term side effects. Conventional chemotherapeutic agents are characterized by neurotoxicity or ototoxicity, poor effect on slow-growing tumors, and may induce new mutations in patients who have lost tumor suppressor function, and therefore are unsuitable for treating VSs. Along with the well-investigated molecular pathophysiology of VS and the increasingly accessible technology such as drug repositioning platform, many molecular targeted inhibitors have been identified and shown certain therapeutic effects in preclinical experiments or clinical trials.

Keywords: vestibular schwannomas, drug therapy, therapeutic targets, VEGFR inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]